Tambon Khlong Nung

Researchers are evaluating the safety, immune response, and effectiveness of the V181 dengue vaccine in healthy children aged 2 to 17 years. This study aims to see if V181 can reduce the number of dengue infections caused by any of the four dengue virus types, regardless of whether participants have had dengue before. The trial is a phase 3, randomized, double-blind, placebo-controlled study sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive a single 0.5 mL dose of either the V181 vaccine or a placebo by subcutaneous injection on Day 1. About 3600 participants are included in the Reactogenicity and Immunogenicity Subset, which will be monitored for safety and immune response for 28 days after vaccination. A smaller group of about 620 participants from this subset will be followed for up to 5 years to assess long-term immune response using specific virus neutralization tests. During the study, participants will be monitored for adverse events, vaccine reactions, and dengue infections, including severity and hospitalization rates, up to 5 years after vaccination. Safety assessments include tracking medically attended and serious adverse events. Immune responses will be measured by antibody levels and seroconversion rates. Participants will have scheduled visits during the first month postvaccination and ongoing follow-ups for several years to evaluate the vaccines long-term effects and protective benefits.

This trial is for adults who have had an acute ischemic stroke caused by a blood clot blocking a brain vessel. It focuses on people whose stroke occurred or was discovered more than 4.5 hours ago, including those who woke up with stroke symptoms. The study aims to find out if the medicine tenecteplase helps recovery when given after this 4.5-hour window, compared to standard medical care. Tenecteplase is already used within 4.5 hours after stroke onset, but this study tests its effect when given later. Participants are randomly assigned to one of two groups one receives a single injection of tenecteplase into a vein, and the other receives the usual standard treatment. Both groups have an equal chance of receiving either treatment. The study lasts about three months, starting with approximately one week of hospital stay. During the study, participants have seven clinical examinations or visits, with the final two visits conducted remotely from home to allow for easier participation. Throughout the study, doctors regularly assess participants recovery using a scale that measures disability and dependence in daily activities. They also monitor overall health and record any side effects. The main outcome measured is the level of recovery 90 days after treatment, comparing the two groups. This includes neurological improvement, bleeding events, and survival over the study period.

Researchers are evaluating the effects of benfotiamine compared to vitamin B1-6-12 in adults with diabetic peripheral neuropathy. This condition causes sensory neuropathy symptoms, numbness, and pain, and the study aims to find out if benfotiamine reduces these symptoms more effectively than vitamin B1-6-12. The trial is a phase 4, randomized, double-blind study designed to compare these treatments over 12 weeks. Participants will be randomly assigned to one of two groups one receiving benfotiamine 150 mg twice daily, and the other receiving a combined vitamin B1 100 mg, B6 5 mg, and B12 65 mcg pill twice daily. Both treatments are given orally for three months and are made to look identical to keep the study blinded. Before enrollment, participants will be screened for vitamin B12 deficiency, and those with low levels will not be eligible. During the study, participants will have two in-person clinic visits at the start and end of the 12-week treatment period, along with two telephone follow-ups. They will continue their usual medications as long as no new neuropathic pain treatments are started and existing doses remain stable. Researchers will assess changes in neuropathy symptoms, numbness, and pain over the course of treatment using standardized symptom scores and patient impressions of change.